Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | TLR2 | O60603 | 3/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.55 |
| ▸ | MDM4 | O15151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30749158 | 1.00 | KMT2A (0.66) | KMT2ATLR2MDM2MDM4TP53 | |
| SCHEMBL7461050 | 0.99 | KMT2A (0.64) | KMT2ATLR2MDM2MDM4TP53 | |
| SCHEMBL30819573 | 0.95 | KMT2A (0.62) | KMT2ATLR2MDM2MDM4TP53 | |
| SCHEMBL30749111 | 0.95 | KMT2A (0.62) | KMT2ATLR2MDM2MDM4TP53 | |
| SCHEMBL19951678 | 0.95 | KMT2A (0.62) | KMT2ATLR2MDM2MDM4TP53 | |
| SCHEMBL8893047 | 0.94 | MDM2 (0.60) | KMT2ATLR2MDM2MDM4TP53 | |
| SCHEMBL8892538 | 0.94 | MDM2 (0.60) | KMT2ATLR2MDM2MDM4TP53 | |
| SCHEMBL29400089 | 0.91 | KMT2A (0.58) | KMT2ATLR2MDM2MDM4TP53 | |
| SCHEMBL29354378 | 0.91 | KMT2A (0.58) | KMT2ATLR2MDM2MDM4TP53 | |
| SCHEMBL30338216 | 0.91 | KMT2A (0.58) | KMT2ATLR2MDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10400010-B2 | Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-03 | — | — | US | disclosed |
| US-10011587-B2 | Multivalent ligands targeting VEGFR | THE METHODIST HOSPITAL SYSTEM (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180155396-A1 | STRUCTURE-BASED PEPTIDE INHIBITORS OF P53 AGGREGATION AS A NEW APPROACH TO CANCER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-07 | — | — | US | disclosed |
| US-9833520-B2 | Labeled, non-peptidic, multivalent integrin antagonist compounds; methods for synthesis and uses thereof | THE METHODIST HOSPITAL RESEARCH INSTITUTE (US) | 2017-12-05 | — | — | US | disclosed |
| US-9833520-B2 | Labeled, non-peptidic, multivalent integrin antagonist compounds; methods for synthesis and uses thereof | THE METHODIST HOSPITAL RESEARCH INSTITUTE (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170073328-A1 | MULTIVALENT LIGANDS TARGETING VEGFR | THE METHODIST HOSPITAL SYSTEM | 2017-03-16 | — | — | US | disclosed |
| WO-2015175750-A1 | MULTIVALENT LIGANDS TARGETING VEGFR | THE METHODIST HOSPITAL SYSTEM (US) | 2015-11-19 | — | — | WO | disclosed |
| US-20140044646-A1 | Labeled, Non-Peptidic, Multivalent Integrin Antagonist Compounds; Methods for Synthesis and Uses Thereof | THE METHODIST HOSPITAL RESEARCH INSTITUTE (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140044646-A1 | Labeled, Non-Peptidic, Multivalent Integrin Antagonist Compounds; Methods for Synthesis and Uses Thereof | THE METHODIST HOSPITAL RESEARCH INSTITUTE (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2012103328-A1 | LABELED, NON- PEPTIDIC MULTIVALENT INTEGRIN ALPHA -V - BETA - 3 ANTAGONISTS, COMPOSITIONS CONTAINING THEM AND THEIR USE | THE METHODIST HOSPITAL RESEARCH INSTITUTE (US) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073328-A1 | MULTIVALENT LIGANDS TARGETING VEGFR | KDR, FLT4, FLT1 | KMT2A 2740/4885TLR2 867/4885MDM2 251/4885 |
| US-20140044646-A1 | Labeled, Non-Peptidic, Multivalent Integrin Antagonist Compounds; Methods for Synthesis and Uses Thereof | ITGB3, ITGAV, ITGB1 | KMT2A 2905/4885TLR2 1030/4885MDM2 3076/4885 |
| US-20180155396-A1 | STRUCTURE-BASED PEPTIDE INHIBITORS OF P53 AGGREGATION AS A NEW APPROACH TO CANCER THERAPEUTICS | TP53, TP53BP1, API5 | KMT2A 4658/4885TLR2 4867/4885MDM2 7/4885 |
| US-10011587-B2 | Multivalent ligands targeting VEGFR | KDR, FLT4, FLT1 | KMT2A 2740/4885TLR2 867/4885MDM2 251/4885 |
| US-10400010-B2 | Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics | TP53, TP53BP1, API5 | KMT2A 4658/4885TLR2 4867/4885MDM2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.